Company news
Cyclopharm Limited (ASX:CYC) news
Cyclopharm Limited news releases on 6ix. Latest, Feb 5, 2024: Cyclopharm Trading and USA Launch Update
Press releases — page 2
Cyclopharm Trading and USA Launch Update
February 5, 2024
Cyclopharm Signs First USA Contract for Technegas
December 4, 2023
Cyclopharm Receives USFDA Approval for Technegas
October 1, 2023
Investor Presentation Correction
September 26, 2023
Cyclopharm Investor Update
September 25, 2023
Litigation Update and Receipt of Settlement Payment
August 24, 2023
Half Year Accounts
August 22, 2023
USFDA Approval Process Update
August 8, 2023
Cyclopharm 2023 Half Year Accounts Update - Record Revenues
July 16, 2023
Notification of buy-back - CYC
May 16, 2023
Cyclopharm Confirms USFDA Scheduled Inspection Date
May 8, 2023
USFDA Confirms Technegas Six Month Review Period
April 24, 2023
Technegas Enters Final Six Month USFDA Review Cycle
March 30, 2023
Dividend/Distribution - CYC
February 20, 2023
Cyclopharm Receives $1.64m R&D Refund
November 29, 2022
Half Year 2022 Results
August 16, 2022
Technegas Used In Multicenter COVID Study
July 6, 2022
1H 2022 Business Update - Record Revenues
July 4, 2022
S&P DJI Announces March 2022 Quarterly Rebalance
March 4, 2022
Cyclopharm USFDA Update
February 3, 2022
Half Year 2021 Financial Results
August 22, 2021
CYC First Half Trading Update
July 1, 2021
Managing Directors Address to Shareholders
May 4, 2021
CYC 2021 AGM Presentation
May 4, 2021
Chairmans Address to Shareholders
May 4, 2021
S&P DJI Announces March 2021 Quarterly Rebalance
March 12, 2021
Confirmation of Technegas USFDA Timetable
March 11, 2021
Cyclopharm Receives $3.1M R&D Tax Incentive for FY2020
February 5, 2021
Cyclopharm Successfully Completes A$30 Million Placement
January 24, 2021
SNMMI Requests USFDA to Expedite Approval For Technegas
January 22, 2021
USFDA Approval Progress for Technegas and Business Update
January 14, 2021
Cyclopharm Investor Presentation
September 22, 2020
Technegas USA Trial Successfully Meets Primary Endpoint
September 15, 2020
CYC 1H2020 Business Update
July 6, 2020
USFDA Approval to File Received for Technegas
May 26, 2020
Technegas Approved in Russia
May 25, 2020
USFDA Grants Cyclopharm USD$2.9m Application Fee Waiver
April 13, 2020
Cyclopharm Lodges NDA for Technegas with the USFDA
March 29, 2020
Cyclopharm Company Update
March 24, 2020
CYC Institutional Placement - Premium To Share Price
December 19, 2019
Pause in Trading
December 18, 2019
CYC Business Update
December 10, 2019
CYC Half Yearly Reports and Accounts
August 22, 2019
Announcement of buy-back - Appendix 3C
May 21, 2019
CYC Update - R&D Tax Incentive, USFDA, German Litigation
January 24, 2019
CANM Endorses Technegas
December 18, 2018
Positive USFDA Meeting - Technegas sales expected in 2019
October 11, 2018
Cyclopharm 2018 First Half Preliminary Headline Update
August 8, 2018
CYC 2018 AGM Presentation
May 29, 2018
Better Defining Airways Disease with Technegas
May 17, 2018